Inhibitory effects of mitotane on viability and secretory activity in mouse gonadotroph cell lines

Reproductive Toxicology

Volumn 45, Issue , 2014, Pages 71-76

  Gentilin, Erica ^a   Molè, Daniela ^a   Gagliano, Teresa ^a   Minoia, Mariella ^a   Ambrosio, Maria Rosaria ^a   degli Uberti, Ettore C ^a   Zatelli, Maria Chiara ^a  

^a UNIVERSITY OF FERRARA   (Italy)

Author keywords

Adrenocortical carcinoma; FSH; Hypogonadism; LH; Mitotane; Pituitary function

Indexed keywords

CASPASE 3; CASPASE 7; FOLLITROPIN; LUTEINIZING HORMONE; MITOTANE; ANTINEOPLASTIC HORMONE AGONISTS AND ANTAGONISTS; CASP7 PROTEIN, MOUSE;

ANIMAL CELL; APOPTOSIS; ARTICLE; CELL CYCLE CHECKPOINT; CELL VIABILITY; CELLULAR DISTRIBUTION; CELLULAR SECRETION; CYTOTOXICITY; DISEASE ASSOCIATION; ENZYME ACTIVITY; FOLLITROPIN RELEASE; GONADOTROPIN SECRETING CELL; HYPOGONADISM; HYPOPHYSIS FUNCTION; LUTEINIZING HORMONE RELEASE; MOUSE; NONHUMAN; ANIMAL; CELL CYCLE; CELL LINE; CELL SURVIVAL; CYTOLOGY; DRUG EFFECTS; METABOLISM; TOXICITY;

ANIMALS; ANTINEOPLASTIC AGENTS, HORMONAL; APOPTOSIS; CASPASE 3; CASPASE 7; CELL CYCLE; CELL LINE; CELL SURVIVAL; FOLLICLE STIMULATING HORMONE; GONADOTROPHS; LUTEINIZING HORMONE; MICE; MITOTANE;

EID: 84896729551     PISSN: 08906238     EISSN: 18731708     Source Type: Journal    
DOI: 10.1016/j.reprotox.2014.01.008     Document Type: Article

References (30)

1. Tacon L.J., Prichard R.S., Soon P.S., Robinson B.G., Clifton-Bligh R.J., Sidhu S.B. Current and emerging therapies for advanced adrenocortical carcinoma. Oncologist 2011, 16:36-48. 10.1634/theoncologist.2010-0270.
2. Glover A.R., Ip J.C., Zhao J.T., Soon P.S., Robinson B.G., Sidhu S.B. Current management options for recurrent adrenocortical carcinoma. Oncol Targets Ther 2013, 6:635-643. 10.2147/OTT.S34956.
3. Allolio B., Fassnacht M. Adrenocortical carcinoma: clinical update. J Clin Endocrinol Metab 2006, 91:2027-2037. 10.1210/jc.2005-2639.
4. Fassnacht M., Allolio B. Clinical management of adrenocortical carcinoma. Best Pract Res Clin Endocrinol Metab 2009, 23:273-289. 10.1016/j.beem.2008.10.008.
5. Wängberg B., Khorram-Manesh A., Jansson S., Nilsson B., Nilsson O., Jakobsson C.E., et al. The long-term survival in adrenocortical carcinoma with active surgical management and use of monitored mitotane. Endocr-Relat Cancer 2010, 17:265-272. 10.1677/ERC-09-0190.
6. Daffara F., De Francia S., Reimondo G., Zaggia B., Aroasio E., Porpiglia F., et al. Prospective evaluation of mitotane toxicity in adrenalcortical cancer patients treated adjuvantly. Endocr-Relat Cancer 2008, 15:1043-1053. 10.1677/ERC-08-0103.
7. Zatelli M.C., Gentilin E., Daffara F., Tagliati F., Reimondo G., Carandina G., et al. Therapeutic concentrations of mitotane (o,p'-DDD) inhibit thyrotroph cell viability and TSH expression and secretion in a mouse cell line model. Endocrinology 2010, 151:2453-2461. 10.1210/en.2009-1404.
8. Hescot S., Slama A., Lombès A., Paci A., Remy H., Leboulleux S., et al. Mitotane alters mitochondrial respiratory chain activity by inducing cytochrome c oxidase defect in human adrenocortical cells. Endocr Relat Cancer 2013, 20(May (3)):371-381. 10.1530/ERC-12-0368.
9. Zsippai A., Szabó D.R., Tömböl Z., Szabó P.M., Eder K., Pállinger E., et al. Effects of mitotane on gene expression in the adrenocortical cell line NCI-H295R: a microarray study. Pharmacogenomics 2012, 13(September (12)):1351-1361. 10.2217/pgs.12.116.
10. Gentilin E., Tagliati F., Terzolo M., Zoli M., Lapparelli M., Minoia M., et al. Mitotane reduces human and mouse ACTH-secreting pituitary cells viability and function. J Endocrinol 2013, 218:275-285. 10.1530/JOE-13-0210.
11. Baszko-Błaszyk D., Ochmańska K., Waśko R., Sowiński J. Pregnancy in a patient with adrenocortical carcinoma during treatment with Mitotane-a case report. Endokrynol Pol 2011, 62:186-188.
12. Gentilin E., Tagliati F., Filieri C., Molè D., Minoia M., Ambrosio M.R., et al. miR-26a plays an important role in cell cycle regulation in ACTH-secreting pituitary adenomas by modulating protein kinase Cδ. Endocrinology 2013, 154:1690-1700. 10.1210/en.2012-2070.
13. Gagliano T., Bellio M., Gentilin E., Molè D., Tagliati F., Schiavon M., et al. mTOR, p70S6K, AKT, and ERK1/2 levels predict sensitivity to mTOR and PI3K/mTOR inhibitors in human bronchial carcinoids. Endocr Relat Cancer 2013, 20:463-475. 10.1530/ERC-13-0042.
14. Tagliati F., Gentilin E., Buratto M., Molè D., degli Uberti E.C., Zatelli M.C. Magmas, a gene newly identified as overexpressed in human and mouse ACTH-secreting pituitary adenomas, protects pituitary cells from apoptotic stimuli. Endocrinology 2010, 151:4635-4642. 10.1210/en.2010-0441.
15. Molè D., Gentilin E., Gagliano T., Tagliati F., Bondanelli M., Pelizzo M.R., et al. Protein kinase C: a putative new target for the control of human medullary thyroid carcinoma cell proliferation in vitro. Endocrinology 2012, 153:2088-2098. 10.1210/en.2011-1988.
16. Minoia M., Gentilin E., Molè D., Rossi M., Filieri C., Tagliati F., et al. Growth hormone receptor blockade inhibits growth hormone-induced chemoresistance by restoring cytotoxic-induced apoptosis in breast cancer cells independently of estrogen receptor expression. J Clin Endocrinol Metab 2012, 97:E907-E916. 10.1210/jc.2011-3340.
17. Gagliano T., Filieri C., Minoia M., Buratto M., Tagliati F., Ambrosio M.R., et al. Cabergoline reduces cell viability in non-functioning pituitary adenomas by inhibiting vascular endothelial growth factor secretion. Pituitary 2013, 16:91-100. 10.1007/s11102-012-0380-1.
18. Molè D., Gagliano T., Gentilin E., Tagliati F., Pasquali C., Ambrosio M.R., et al. Targeting protein kinase C by Enzastaurin restrains proliferation and secretion in human pancreatic endocrine tumors. Endocr Relat Cancer 2011, 18:439-450. 10.1530/ERC-11-0055.
19. Zatelli M.C., Luchin A., Tagliati F., Leoni S., Piccin D., Bondanelli M., et al. Cyclooxygenase-2 inhibitors prevent the development of chemoresistance phenotype in a breast cancer cell line by inhibiting glycoprotein p-170 expression. Endocr Relat Cancer 2007, 14:1029-1038. 10.1677/ERC-07-0114.
20. Zatelli M.C., Piccin D., Tagliati F., Bottoni A., Ambrosio M.R., Margutti A., et al. Dopamine receptor subtype 2 and somatostatin receptor subtype 5 expression influences somatostatin analogs effects on human somatotroph pituitary adenomas in vitro. J Mol Endocrinol 2005, 35:333-341. 10.1677/jme.1.01876.
21. Nader N., Raverot G., Emptoz-Bonneton A., Déchaud H., Bonnay M., Baudin E., et al. Mitotane has an estrogenic effect on sex hormone-binding globulin and corticosteroid-binding globulin in humans. J Clin Endocrinol Metab 2006, 91:2165-2170. 10.1210/jc.2005-2157.
22. Chortis V., Taylor A.E., Schneider P., Tomlinson J.W., Hughes B.A., O'Neil D.M., et al. Mitotane therapy inadrenocortical cancer induces CYP3A4 and inhibits 5α-reductase, explaining the need for personalized glucocorticoid and androgen replacement. J Clin Endocrinol Metab 2013, 98:161-171. 10.1210/jc.2012-2851.
23. Lehmann T.P., Wrzesiński T., Jagodziński P.P. The effect of mitotane on viability, steroidogenesis and gene expression in NCI-H295R adrenocortical cells. Mol Med Rep 2013, 7:893-900. 10.3892/mmr.2012.1244.
24. Stigliano A., Cerquetti L., Borro M., Gentile G., Bucci B., Misiti S., et al. Modulation of proteomic profile in H295R adrenocortical cell line induced by mitotane. Endocr Relat Cancer 2008, 15:1-10. 10.1677/ERC-07-0003.
25. Fang V.S. Cytotoxic activity of 1-(o-chlorophenyl)-1-(p-chlorophenyl)-2,2-dichloroethane (mitotane) and its analogs on feminizing adrenal neoplastic cells in culture. Cancer Res 1979, 39:139-145.
26. Cerquetti L., Bucci B., Marchese R., Misiti S., De Paula U., Miceli R., et al. Mitotane increases the radiotherapy inhibitory effect and induces G2-arrest in combined treatment on both H295R and SW13 adrenocortical cell lines. Endocr Relat Cancer 2008, 15:623-634. 10.1677/erc.1.1315.
27. Pushkarev V.M., Tronko N.D., Kostyuchenko N.N., Mikosha A.S. Effect of o,p'-DDD and Li+ on apoptotic DNA fragmentation in conventionally normal and tumour tissues of human adrenal cortex. Ukr Biokhim Zh 2007, 79:44-49.
28. Poli G., Guasti D., Rapizzi E., Fucci R., Canu L., Bandini A., et al. Morphofunctional effects of mitotane on mitochondria in human adrenocortical cancer cells. Endocr-Relat Cancer 2013, 20:537-550. 10.1530/ERC-13-0150.
29. Hahner S., Fassnacht M. Mitotane for adrenocortical carcinoma treatment. Curr Opin Investig Drugs 2005, 6:386-394.
30. Lund B.O., Bergman A., Brandt I. In vitro macromolecular binding of 2-(2-chlorophenyl)-2-(4-chlorophenyl)-1,1-dichloroethane (o,p'-DDD) in the mouse lung and liver. Chem Biol Interact 1989, 70(1-2):63-72.